



Contact

Aptevo Therapeutics Inc.
 2401 4th Avenue, Suite 1050
 Seattle, WA 98121

General Inquiries


Tel: 206-838-0500
 Fax: 206-838-0503

Investor Relations & Communications

Miriam Weber Miller
 Tel: 206-859-6628
 Email: ir@apvo.com or Millerm@apvo.com

Aptevo Therapeutics (Nasdaq: APVO) is a clinical-stage biotechnology bispecifics company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies.

Investment Highlights



Diversified Pipeline Offers Multiple Opportunities for Partnering

Program (Target)	Potential Indication(s)	Preclinical	Phase 1 (First-in-Human)	Phase 2	Notes
APVO436 (CD3 x CD123)	Frontline AML	→	→		Orphan Drug Designation APVO436 in combination with venetoclax and azacitidine
ALG.APV-527* (4-1BB x 5T4)	NSCLC, Head & Neck, Colorectal, Pancreatic, Breast, Other Solid Tumors	→	→		Phase 1 trial ongoing, interim results 2Q24
APVO711 (PD-L1 x CD40)	Multiple solid tumors	→			Preclinical studies ongoing
APVO603 (4-1BB x OX40)	Multiple solid tumors	→			IND enabling studies ongoing
APVO442 (PSMA x CD3)	Prostate Cancer	→			IND enabling studies ongoing

*Partnered with Alligator Bioscience

